Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.76 |
| ▸ | GUSB | P08236 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252006 | 0.91 | DGAT1 (0.78) | DGAT1GUSBABL1CHEK2 | |
| SCHEMBL1252018 | 0.91 | DGAT1 (0.68) | DGAT1GUSBABL1CHEK2 | |
| SCHEMBL10299681 | 0.88 | DGAT1 (0.81) | DGAT1GUSBCHEK2EGFRERBB2 | |
| SCHEMBL1250481 | 0.88 | DGAT1 (0.86) | DGAT1GUSBNPC1ALDH1A1HPGD | |
| SCHEMBL30565806 | 0.86 | DGAT1 (1.00) | DGAT1GUSBNPC1ALDH1A1HPGD | |
| SCHEMBL21354092 | 0.86 | DGAT1 (1.00) | DGAT1GUSBNPC1ALDH1A1HPGD | |
| SCHEMBL1250476 | 0.82 | DGAT1 (0.69) | DGAT1GUSBALDH1A1CHEK2 | |
| SCHEMBL1252086 | 0.79 | DGAT1 (0.87) | DGAT1GUSBNPC1ALDH1A1HPGD | |
| SCHEMBL10299677 | 0.75 | DGAT1 (0.83) | DGAT1GUSBALDH1A1HPGDCHEK2 | |
| SCHEMBL1250444 | 0.74 | DGAT1 (0.63) | DGAT1GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | claimed |
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | claimed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | claimed |
| WO-2009112445-A1 | METHOD OF INCREASING CELLULAR PHOSPHATIDYL CHOLINE BY DGAT1 INHIBITION | NOVARTIS AG (CH) | 2009-09-17 | — | — | WO | claimed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | claimed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | claimed |
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| EP-2205595-B1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8217065-B2 | Organic compounds | NOVARTIS AG (SE) | 2012-07-10 | — | — | US | disclosed |
| US-8217065-B2 | Organic compounds | NOVARTIS AG (SE) | 2012-07-10 | — | — | US | disclosed |
| US-8217065-B2 | Organic compounds | NOVARTIS AG (SE) | 2012-07-10 | — | — | US | disclosed |
| US-20110077277-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-20110077277-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-03-31 | — | — | US | disclosed |
| US-7879850-B2 | such as 6-[5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-2-(2,6-dichloro-phenyl)-1H-benzoimidazole, having diacylglycerol O-acyl transferase inhibitory activity, used for the treatment of impaired glucose tolerance, non-insulin dependent diabetes or obesity | NOVARTIS AG (CH) | 2011-02-01 | — | — | US | disclosed |
| EP-2205595-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| US-20090186891-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-23 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077277-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885GUSB 217/4885NPC1 50/4885 |
| US-20090186891-A1 | ORGANIC COMPOUNDS | DGAT1, DGAT2, SOAT1 | DGAT1 1/4885GUSB 217/4885NPC1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.